Vestcor Inc Has $2.41 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Vestcor Inc increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 77.8% in the third quarter, Holdings Channel.com reports. The firm owned 3,772 shares of the company’s stock after buying an additional 1,651 shares during the quarter. Vestcor Inc’s holdings in IDEXX Laboratories were worth $2,410,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. Empowered Funds LLC boosted its holdings in shares of IDEXX Laboratories by 6.6% during the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock worth $646,000 after buying an additional 95 shares in the last quarter. Sivia Capital Partners LLC purchased a new stake in IDEXX Laboratories in the 2nd quarter valued at about $265,000. Savant Capital LLC lifted its holdings in IDEXX Laboratories by 88.1% during the second quarter. Savant Capital LLC now owns 3,955 shares of the company’s stock worth $2,121,000 after acquiring an additional 1,852 shares during the period. Vestmark Advisory Solutions Inc. purchased a new position in shares of IDEXX Laboratories in the 2nd quarter worth about $828,000. Finally, Summit Investment Advisors Inc. increased its stake in shares of IDEXX Laboratories by 1.7% during the 1st quarter. Summit Investment Advisors Inc. now owns 3,460 shares of the company’s stock worth $1,453,000 after purchasing an additional 57 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In other news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the transaction, the chief executive officer directly owned 83,606 shares of the company’s stock, valued at $54,975,125.30. This represents a 21.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael G. Erickson sold 5,371 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the completion of the transaction, the executive vice president directly owned 12,693 shares in the company, valued at approximately $7,963,334.34. The trade was a 29.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 45,957 shares of company stock worth $29,862,109 in the last 90 days. Insiders own 0.98% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Weiss Ratings downgraded shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. UBS Group cut their target price on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research note on Tuesday, February 3rd. Piper Sandler decreased their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Wall Street Zen downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, Barclays cut their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Seven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $783.33.

IDEXX Laboratories Stock Down 1.9%

Shares of IDEXX Laboratories stock opened at $598.85 on Wednesday. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98. The company has a market cap of $47.68 billion, a P/E ratio of 45.82, a PEG ratio of 3.71 and a beta of 1.66. The company’s fifty day simple moving average is $663.72 and its two-hundred day simple moving average is $668.13.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.